Pharma Focus Asia
KP - Choose our fully recyclable blister films

Breakthrough Gedatolisib Therapy Discovered for the Treatment of Metastatic Breast Cancer

Celcuity Inc discovered Gedatolisib new therapy for the treatment of HR+/HER2- Metastatic Breast Cancer.

Gedatolisib, the first-in-class pan-PI3K/mTOR inhibitor, is applicable for patients progressed with CDK4/6 therapy and a non-steroidal aromatase inhibitor.

Gedatolisib is a potent, reversible dual inhibitor selectively targeting all Class I PI3K isoforms and mTOR. Moreover, mechanism action of Gedatolisib and pharmacokinetic properties can be highly varied from currently available otherinvestigational therapies that target PI3K or mTOR alone or together.

Class 1 PI3K isoforms and mTOR limits the potential growth of drug resistance when compared to that of isoform specific PI3K or mTOR specific inhibitors.

In Phase 1b clinical trial, gedatolisib evaluated manageable side effects in combination with palbociclib and endocrine therapy in patients with HR+/HER2- advanced breast cancer.In addition, phase 3 trial evaluating gedatolisib in patients with HR+/HER2- advanced breast cancer in 2022.

U.S. Food and Drug Administration (FDA) grants Breakthrough Therapy designation for Gedatolisib for Treatment of HR+/HER2- Metastatic Breast Cancer.

Latest Issue
Get instant
access to our latest e-book
THERMOFISHER SEACertara - Is your drug program on trackMasterControl - Manufacturing demoMasterControl - QMS demoThermo Fisher Scientific - Rapid Mycoplasma TestingThermoFisher Scientific - Save costs on your downstream process todayMerck - Mobius® productsThermo Fisher Scientific - Peptones5th Annual Pharma Manufacturing and Automation Convention 2023DUPHAT 202410TH ANNUAL GCC PHARMACY CONGRESS 2023Reuters Events - Pharma Customer Engagement USA 202314th Annual Emirates Cardiac Society Conference 2023The International Hand & Wrist Congress 2023LabAsia 2023Pharma & Patient USA 2023Pharma Customer Engagement Europe 2023CHEMICAL INDONESIA 2024INALAB 2024